Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BIO101 in Age-Related Sarcopenia (SARA-INT)
2017-003932-35Phase 2Completed
- Sponsor
- Biophytis
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 20-hydroxyecdysone in Sarcopenia and Sarcopenic Obesity (SO) (3 arms), sponsored by Biophytis. Primary endpoint: Gait speed during 400-meter walk test. Started Oct 2017; status: completed.
02
Drugs
20-hydroxyecdysone
03
Conditions
SarcopeniaSarcopenic Obesity (SO)
Beyond the preview
Go deeper on 2017-003932-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003932-35.